How much wiggle room do sponsors have when the US FDA asks them to conduct pediatric studies? The question is again at issue in Amgen Inc.'s suit against FDA objecting to the agency's denial of pediatric exclusivity for Sensipar (cinacalcet).
The complaint specifically addresses when studies "fairly respond" to the agency's written request for them. FDA contends that...





